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Summary: Highly-pathogenic avian influenza A H5 viruses have been identified in birds in the United States 
since December 2014. The purpose of this HAN Advisory is to notify public health workers and clinicians of the 
potential for human infection with these viruses and to describe CDC recommendations for patient investigation 





Between December 15, 2014, and May 29, 2015, the US Department of Agriculture (USDA) confirmed more than 
200 findings of birds infected with highly-pathogenic avian influenza (HPAI) A (H5N2), (H5N8), and (H5N1)1 
viruses. The majority of these infections have occurred in poultry, including backyard and commercial flocks. 
USDA surveillance indicates that more than 40 million birds have been affected (either infected or exposed) in 20 
states. These are the first reported infections with these viruses in US wild or domestic birds. 
 
While these recently-identified HPAI H5 viruses are not known to have caused disease in humans, their 
appearance in North American birds may increase the likelihood of human infection in the United States. Human 
infection with other avian influenza viruses, including a different HPAI (H5N1) virus found in Asia, Africa, and 
other parts of the world; HPAI (H5N6) virus; and (H7N9) virus, has been associated with severe, sometimes fatal, 
disease. Previous human infections with other avian viruses have most often occurred after unprotected direct 
physical contact with infected birds or surfaces contaminated by avian influenza viruses, being in close proximity 
to infected birds, or visiting a live poultry market. Human infection with avian influenza viruses has not occurred 
from eating properly cooked poultry or poultry products. For more information on the origin of the recently-
identified HPAI H5 viruses in the United States, their clinical presentation in birds, and their suspected clinical 
presentation in humans, please see http://www.cdc.gov/flu/avianflu/hpai/hpai-background-clinical-illness.htm.  
 
CDC considers the risk to the general public from these newly-identified US HPAI H5 viruses to be low; however, 
people with close or prolonged unprotected contact with infected birds or contaminated environments may be at 
greater risk of infection. Until more is known about these newly-identified HPAI H5 viruses, public health 
recommendations are largely consistent with guidance for influenza viruses associated with severe disease in 
humans (e.g., HPAI H5N1 viruses that have caused human infections with high mortality in other countries). 
Currently, CDC considers these newly-identified HPAI H5 viruses as having the potential to cause severe disease 
in humans and recommends the following: 
 
Clinicians should consider the possibility of HPAI H5 virus infection in persons showing signs or 
symptoms of respiratory illness who have relevant exposure history. This includes persons who have had 
contact with potentially-infected birds (e.g., handling, slaughtering, defeathering, butchering, culling, preparation 
                                                 
1The H5N1 virus isolated from US wild birds is a new mixed-origin virus (a “reassortant”) that is genetically 
different from the HPAI H5N1 viruses that have caused human infections with high mortality in other countries 
(notably in Asia and Africa). No human infections with this new reassortant H5N1 virus have been reported in any 
country. 
for consumption); direct contact with surfaces contaminated with feces or parts (carcasses, internal organs, etc.) 
of potentially-infected birds; and persons who have had prolonged exposure to potentially-infected birds in a 
confined space.  
 
State health departments are encouraged to investigate potential human cases of HPAI H5 virus infection 
as described below and should notify CDC within 24 hours of identifying a case under investigation. 
Rapid detection and characterization of novel influenza A viruses in humans remain critical components of 
national efforts to prevent further cases, evaluate clinical illness associated with them, and assess any ability for 
these viruses to spread among humans. 
 
People should avoid unprotected exposure to sick or dead birds, bird feces, litter, or materials 
contaminated with suspected or confirmed HPAI H5 viruses. All recommended personal protective 
equipment (PPE) should be worn when in direct or close contact (within about 6 feet) with sick or dead poultry, 
poultry feces, litter or materials contaminated with suspected or confirmed HPAI H5 viruses.  
 
People exposed to HPAI H5-infected birds (including people wearing PPE) should be monitored for signs 
and symptoms consistent with influenza beginning after their first exposure and for 10 days after their 
last exposure. Influenza antiviral prophylaxis may be considered to prevent infection (see below). Persons who 
develop respiratory illness after exposure to HPAI H5-infected birds should be tested immediately for influenza by 
the state health department and be given influenza antiviral treatment (see below). State health departments are 
encouraged to investigate all possible human infections with HPAI H5 virus and should notify CDC promptly when 
testing for avian influenza in people. 
 
Recommendations for Surveillance and Testing 
Patients who meet clinical and exposure criteria should be tested for HPAI H5 virus infection by reverse-
transcription polymerase chain reaction (RT-PCR) assay using H5-specific primers and probes. Additional 
persons in whom clinicians suspect HPAI H5 virus infection also may be tested.  
Clinical Illness Criteria:  Patients with new-onset influenza-like illness (ILI) or acute respiratory infection (ARI), 
which may include conjunctivitis, which has been associated with avian influenza in humans. Clinical presentation 
of persons infected with these HPAI H5 viruses may vary somewhat from seasonal influenza or infection with 
other novel influenza A viruses. Thus, clinicians are encouraged to consider a range of respiratory signs and 
symptoms when evaluating a patient with appropriate exposure for HPAI H5 virus infection. 
Bird Exposure Criteria:  Patients who have had recent contact2 (within 10 days of illness onset) with potentially-
infected (i.e., sick or dead birds, or flocks where HPAI H5 virus infection has been confirmed) in any of the 
following categories: 
 Domestic poultry (e.g., chickens, turkeys, ducks, geese) 
 Wild aquatic birds (e.g., ducks, geese, swans) 
 Birds of prey (e.g., falcons) that have had contact with wild aquatic birds 
 
Multiple respiratory tract specimens should be collected from persons with suspected HPAI H5 virus infection, 
including nasopharyngeal, nasal, and throat swabs. Patients with severe respiratory disease also should have 
lower respiratory tract specimens collected, if possible. For more information on surveillance and testing of 
persons under investigation for avian HPAI H5 virus infection, please see http://www.cdc.gov/flu/avianflu/severe-
potential.htm. 
 
Recommendations for Worker Protection 
To reduce their risk of HPAI H5 virus infection, poultry workers and responders should avoid unprotected direct 
physical contact with sick or dead birds, and carcasses, feces, or litter from potentially-infected poultry. Poultry 
workers should wear recommended PPE when in direct contact with sick or dead birds, and carcasses, feces, or 
                                                 
2Contact may include: direct contact with birds (e.g., handling, slaughtering, defeathering, butchering, culling, 
preparation for consumption); or direct contact with surfaces contaminated with feces or bird parts (carcasses, 
internal organs, etc.); or prolonged exposure to birds in a confined space. 
litter from potentially-infected poultry, and when going into any buildings with sick or dead poultry, or carcasses, 
feces, or litter from potentially-infected poultry. Workers should receive training on and demonstrate an 
understanding of when to use PPE; what PPE is necessary; how to properly put on, use, take off, properly 
dispose of, and maintain PPE; and the limitations of PPE. For additional guidance on worker protection, please 
see http://www.cdc.gov/flu/avianflu/h5/worker-protection-ppe.htm.  
 
Recommendations for Infection Control 
For patients presenting for medical care or evaluation who have illness consistent with influenza and recent 
exposure to potentially-infected birds, standard, contact, and airborne precautions are recommended. For 
additional guidance on infection control precautions for patients who may be infected with HPAI H5 virus, please 
refer to guidance for infections with novel influenza A viruses associated with severe disease found at 
http://www.cdc.gov/flu/avianflu/novel-flu-infection-control.htm.  
 
Recommendations for Influenza Antiviral Treatment and Chemoprophylaxis 
Chemoprophylaxis with influenza antiviral medications can be considered for all persons meeting bird exposure 
criteria. Decisions to initiate antiviral chemoprophylaxis should be based on clinical judgment, with consideration 
given to the type of exposure and to whether the exposed person is at high risk for complications from influenza 
(http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm).  
Chemoprophylaxis is not routinely recommended for personnel who used proper PPE while handling sick or 
potentially-infected birds or decontaminating infected environments (including animal disposal). 
If antiviral chemoprophylaxis is initiated, treatment dosing for the neuraminidase inhibitors oseltamivir or 
zanamivir (one dose twice daily) is recommended instead of the typical antiviral chemoprophylaxis regimen (once 
daily).3 For specific dosage recommendations for treatment by age group, please see Influenza Antiviral 
Medications: Summary for Clinicians (http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm) 
Physicians should consult the manufacturer’s package insert for dosing, limitations of populations studied, 
contraindications, and adverse effects. If exposure was time-limited and not ongoing, five days of medication (one 
dose twice daily) from the last known exposure is recommended.  
Treatment of Symptomatic Persons with Bird Exposure:  Patients meeting bird exposure criteria who develop 
symptoms compatible with influenza should be referred for prompt medical evaluation and empiric initiation of 
influenza antiviral treatment with a neuraminidase inhibitor as soon as possible. Clinical benefit is greatest when 
antiviral treatment is administered early, especially within 48 hours of illness onset. Antiviral treatment should 
not be delayed while waiting for laboratory testing results. For detailed guidance, please see Interim 
Guidance of the Use of Antiviral Medications for the Treatment of Human Infection with Novel Influenza A Viruses 
Associated with Severe Human Disease (http://www.cdc.gov/flu/avianflu/novel-av-treatment-guidance.htm).  
 
Monitoring and Chemoprophylaxis of Close Contacts of Persons with HPAI H5 virus infection:  If a case of human 
infection with HPAI H5 virus is identified in the United States, recommendations for monitoring and 
chemoprophylaxis of close contacts of the infected person are different than those that apply to persons who 
meet bird exposure criteria. For detailed guidance, please see Interim Guidance on Follow-up of Close Contacts 




No human vaccines for HPAI (H5N1), (H5N2), or (H5N8) are available in the United States. Efforts are underway 
to develop vaccines against these HPAI H5 viruses. Seasonal influenza vaccines do not provide any protection 
against human infection with HPAI H5 viruses.  
 
 
                                                 
3
This recommendation for twice daily antiviral chemoprophylaxis dosing frequency is based on limited data that support higher 
chemoprophylaxis dosing in animals for avian A (H5N1) virus (Boltz DA, et al JID 2008;197:1315) and the desire to reduce the 
potential for development of resistance while receiving once daily dosing (BazM, et al NEJM 2009;361:2296; Cane A et al 
PIDJ 2010;29:384; MMWR 2009;58:969). 
 
For More Information 
 
 General information about avian influenza viruses and how they spread (http://www.cdc.gov/flu/avianflu/avian-
in-humans.htm)    
 Past Outbreaks of Avian Influenza in North America 
(http://www.cdc.gov/flu/avianflu/past-outbreaks.htm) 
 Transmission of Avian Influenza A Viruses Between Animals and People 
(http://www.cdc.gov/flu/avianflu/virus-transmission.htm)  
 H5 Viruses in the United States 
http://www.cdc.gov/flu/avianflu/h5/index.htm  
 
 General information about Avian Influenza viruses in birds 
http://www.cdc.gov/flu/avianflu/avian-in-birds.htm  
 




The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and controlling 
diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes 




Categories of Health Alert Network messages:  
Health Alert  Requires immediate action or attention; highest level of importance 
Health Advisory May not require immediate action; provides important information for a specific incident or situation 
Health Update   Unlikely to require immediate action; provides updated information regarding an incident or situation 
HAN Info Service Does not require immediate action; provides general public health information 
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